• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Jasper Therapeutics Inc. (Amendment)

    2/2/24 9:50:12 AM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $JSPR alert in real time by email
    SC 13G/A 1 ea192414-13ga1soleus_jasper.htm AMENDMENT NO. 1 TO SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

     

    JASPER THERAPEUTICS, INC.

    (Name of Issuer)

     

    Common Stock

    (Title of Class of Securities)

     

    471871202

    (CUSIP Number)

     

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐Rule 13d-1(b)

     

    ☒Rule 13d-1(c)

     

    ☐Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    Page 2 of 10

     

    CUSIP NO. 471871202

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Soleus Capital Master Fund, L.P.

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

    (a) ☐ (b) ☐

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH:

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    987,096 (1)

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    987,096 (1)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    987,096 (1)

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    8.8% (2)

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    FI

     

    FOOTNOTES

     

    (1)The shares of common stock reported in this row are held by Soleus Capital Master Fund, L.P. (“Master Fund”). Soleus Capital, LLC is the sole general partner of Master Fund and thus holds voting and dispositive power over the shares held by Master Fund. Soleus Capital Group, LLC is the sole managing member of Soleus Capital, LLC. Mr. Guy Levy is the sole managing member of Soleus Capital Group, LLC. Each of Soleus Capital Group, LLC, Soleus Capital, LLC and Mr. Guy Levy disclaims beneficial ownership of these securities held by Master Fund and this report shall not be deemed an admission that they are the beneficial owners of such securities for purposes of Section 13(d) of the Exchange Act, or for any other purpose, except to the extent of their respective pecuniary interests therein. These share were also reported after giving effect to a one-for-ten reverse stock split of the Issuer conducted on January 4, 2024 (the “Reverse Split”).

     

    (2)This percentage is calculated based upon 11,157,526 shares of common stock outstanding of the Issuer as of October 31, 2023, after giving effect to the Reverse Split, as disclosed in the Issuer’s Quarterly Report on Form 10-Q for the period ended September 30, 2023 that was filed with the Securities and Exchange Commission on November 9, 2023 (the “Form 10-Q”).

     

     

    Page 3 of 10

     

    CUSIP NO. 471871202

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Soleus Capital, LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

    (a) ☐ (b) ☐

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH:
    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    987,096 (1)

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    987,096 (1)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    987,096 (1)

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    8.8% (2)

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    FOOTNOTES

     

    (1)The shares of common stock reported in this row are held by Master Fund. Soleus Capital, LLC is the sole general partner of Master Fund and thus holds voting and dispositive power over the shares held by Master Fund. Soleus Capital Group, LLC is the sole managing member of Soleus Capital, LLC. Mr. Guy Levy is the sole managing member of Soleus Capital Group, LLC. Each of Soleus Capital Group, LLC, Soleus Capital, LLC and Mr. Guy Levy disclaims beneficial ownership of these securities held by Master Fund and this report shall not be deemed an admission that they are the beneficial owners of such securities for purposes of Section 13(d) of the Exchange Act, or for any other purpose, except to the extent of their respective pecuniary interests therein. These share were also reported after giving effect to the Reverse Split.

     

    (2)This percentage is calculated based upon 11,157,526 shares of common stock outstanding of the Issuer as of October 31, 2023, after giving effect to the Reverse Split, as reported in the Form 10-Q.

     

     

    Page 4 of 10

     

    CUSIP NO. 471871202

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Soleus Capital Group, LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

    (a) ☐ (b) ☐

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH:
    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    987,096 (1)

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    987,096 (1)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    987,096 (1)

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    8.8% (2)

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    FOOTNOTES

     

    (1)The shares of common stock reported in this row are held by Master Fund. Soleus Capital, LLC is the sole general partner of Master Fund and thus holds voting and dispositive power over the shares held by Master Fund. Soleus Capital Group, LLC is the sole managing member of Soleus Capital, LLC. Mr. Guy Levy is the sole managing member of Soleus Capital Group, LLC. Each of Soleus Capital Group, LLC, Soleus Capital, LLC and Mr. Guy Levy disclaims beneficial ownership of these securities held by Master Fund and this report shall not be deemed an admission that they are the beneficial owners of such securities for purposes of Section 13(d) of the Exchange Act, or for any other purpose, except to the extent of their respective pecuniary interests therein. These share were also reported after giving effect to the Reverse Split.

     

    (2)This percentage is calculated based upon 11,157,526 shares of common stock outstanding of the Issuer as of October 31, 2023, after giving effect to the Reverse Split, as reported in the Form 10-Q.

     

     

    Page 5 of 10

      

    CUSIP NO. 471871202

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Guy Levy

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

    (a) ☐ (b) ☐

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH:

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    987,096 (1)

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    987,096 (1)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    987,096 (1)

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    8.8% (2)

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN

     

    FOOTNOTES

     

    (1)The shares of common stock reported in this row are held by Master Fund. Soleus Capital, LLC is the sole general partner of Master Fund and thus holds voting and dispositive power over the shares held by Master Fund. Soleus Capital Group, LLC is the sole managing member of Soleus Capital, LLC. Mr. Guy Levy is the sole managing member of Soleus Capital Group, LLC. Each of Soleus Capital Group, LLC, Soleus Capital, LLC and Mr. Guy Levy disclaims beneficial ownership of these securities held by Master Fund and this report shall not be deemed an admission that they are the beneficial owners of such securities for purposes of Section 13(d) of the Exchange Act, or for any other purpose, except to the extent of their respective pecuniary interests therein. These share were also reported after giving effect to the Reverse Split.

     

    (2)This percentage is calculated based upon 11,157,526 shares of common stock outstanding of the Issuer as of October 31, 2023, , after giving effect to the Reverse Split, as reported in the Form 10-Q.

     

     

    Page 6 of 10

     

    Item 1.

     

    (a)Name of Issuer

     

    Jasper Therapeutics, Inc.

     

    (b)Address of Issuer’s Principal Executive Offices

     

    2200 Bridge Pkwy Suite #102

    Redwood City, CA 94065

     

    Item 2.

     

    (a)Name of Person(s) Filing

     

    Soleus Capital Master Fund, L.P.

    Soleus Capital, LLC

    Soleus Capital Group, LLC

    Guy Levy

     

    (b)Address of Principal Business Office or, if none, Residence

     

    Soleus Capital Master Fund, L.P.

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

     

    Soleus Capital, LLC

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

     

    Soleus Capital Group, LLC

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

     

    Guy Levy

    c/o Soleus Capital Management, L.P

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

     

    (c)Citizenship

     

    Soleus Capital Master Fund, L.P. – Cayman Islands

    Soleus Capital, LLC – Delaware

    Soleus Capital Group, LLC – Delaware

    Guy Levy – United States

     

    (d)Title of Class of Securities

     

    Common Stock

     

    (e)CUSIP Number

     

    471871202

     

     

    Page 7 of 10

     

    Item 3.If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
         
    (b)☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
         
    (c)☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. ☐78c).
         
    (d)☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
         
    (e)☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
         
    (f)☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
         
    (g)☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
         
    (h)☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
    (i)☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
         
    (j)☐ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J).
         
    (k)☐ Group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

    Item 4.Ownership.

     

    Reference is made to Items 5 – 11 on the preceding pages of this Schedule 13G.

     

    Master Fund held, as of the close of business on December 31, 2023, and after giving effect to the Reverse Split, an aggregate of 987,096 shares of the common stock of the Issuer. As the general partner of Master Fund, Soleus Capital, LLC may be deemed to have shared power to vote or to direct the vote and to dispose or to direct the disposition of the shares held by Master Fund. As the sole managing member of Soleus Capital, LLC, Soleus Capital Group, LLC may be deemed to have shared power to vote or to direct the vote and to dispose or to direct the disposition of the shares held by Master Fund. As the sole managing member of Soleus Capital Group, LLC, Mr. Guy Levy may be deemed to have shared power to vote or direct the vote and to dispose or to direct the disposition of the Shares held by Master Fund.

     

    Neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission that Mr. Levy, Soleus Capital, LLC or Soleus Capital Group, LLC is the beneficial owner of the shares of the common stock of the Issuer referred to herein for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, or for any other purpose, and such beneficial ownership is expressly disclaimed, except to the extent of their respective pecuniary interests therein.

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    Not applicable.

     

     

    Page 8 of 10

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10.Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose, or with the effect, of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    Page 9 of 10

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 2, 2024 Soleus Capital Master Fund, L.P.
         
      By: Soleus Capital, LLC, its General Partner
         
      By: Soleus Capital Group, LLC, its Managing Manager
         
      By: /s/ Guy Levy
      Name: Guy Levy
      Title: Managing Member
         
    Date: February 2, 2024 Soleus Capital, LLC
         
      By: Soleus Capital Group, LLC, its Managing Manager
         
      By: /s/ Guy Levy
      Name:   Guy Levy
      Title: Managing Member
         
    Date: February 2, 2024 Soleus Capital Group, LLC
         
      By: /s/ Guy Levy
      Name: Guy Levy
      Title: Managing Member
         
    Date: February 2, 2024 /s/ Guy Levy
      Name: Guy Levy

     

    Footnotes:

     

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

     

     

    Page 10 of 10

     

    EXHIBIT A

    JOINT FILING AGREEMENT

     

    Soleus Capital Master Fund, L.P., a Cayman Islands exempted limited partnership, Soleus Capital, LLC, a Delaware limited liability company, Soleus Capital Group, LLC, a Delaware limited liability company, and Guy Levy, an individual, hereby agree to file jointly the statement on Schedule 13G to which this Joint Filing Agreement is attached, and any amendments thereto which may be deemed necessary, pursuant to Regulation 13D-G under the Securities Exchange Act of 1934, as amended.

     

    It is understood and agreed that each of the parties hereto is responsible for the timely filing of such statement and any amendments thereto, and for the completeness and accuracy of the information concerning such party contained therein, but such party is not responsible for the completeness or accuracy of information concerning the other party unless such party knows or has reason to believe that such information is inaccurate.

     

    It is understood and agreed that a copy of this Agreement shall be attached as an exhibit to the statement on Schedule 13G, and any amendments hereto, filed on behalf of each of the parties hereto.

     

    Date: February 2, 2024 Soleus Capital Master Fund, L.P.
         
      By: Soleus Capital, LLC, its General Partner
         
      By: Soleus Capital Group, LLC, its Managing Manager
         
      By: /s/ Guy Levy
      Name:   Guy Levy
      Title: Managing Member
         
    Date: February 2, 2024 Soleus Capital, LLC
         
      By: Soleus Capital Group, LLC, its Managing Manager
         
      By: /s/ Guy Levy
      Name:    Guy Levy
      Title: Managing Member
         
    Date: February 2, 2024 Soleus Capital Group, LLC
         
      By: /s/ Guy Levy
      Name: Guy Levy
      Title: Managing Member
         
    Date: February 2, 2024 /s/ Guy Levy
      Name: Guy Levy

     

     

     

     

     

     

    Get the next $JSPR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $JSPR

    DatePrice TargetRatingAnalyst
    1/13/2026$17.00Buy
    Rodman & Renshaw
    7/8/2025$4.00Outperform → Market Perform
    BMO Capital Markets
    7/8/2025$5.00Outperform → Sector Perform
    RBC Capital Mkts
    7/7/2025Overweight → Neutral
    Cantor Fitzgerald
    7/7/2025Outperform → Mkt Perform
    William Blair
    2/13/2025$38.00Buy
    UBS
    12/6/2024$63.00Outperform
    BMO Capital Markets
    9/9/2024$70.00Mkt Outperform
    JMP Securities
    More analyst ratings

    $JSPR
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Jasper Therapeutics Inc.

    SCHEDULE 13G - Jasper Therapeutics, Inc. (0001788028) (Subject)

    2/11/26 1:38:43 PM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Jasper Therapeutics Inc.

    SCHEDULE 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)

    1/26/26 3:29:02 PM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Jasper Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Jasper Therapeutics, Inc. (0001788028) (Filer)

    1/8/26 7:06:57 AM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $JSPR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria

    67% of additional patients (n=6) enrolled in the BEACON study achieved a complete response at 12 weeks with a mean UAS7 reduction of 31 points  75% of CSU participants (n=36) enrolled in the open label extension study achieved a complete response or well controlled disease at 12 weeks With a median duration of follow up of more than 200 days on 63 participants in the open label extension study, KIT related AEs were low in frequency and predominantly low-grade events that resolved while on study BEACON and open label extension data sets are now sufficient to select doses for the Phase 2b study of briquilimab in CSU planned to commence in the second half of 2026 Company to host conference

    1/8/26 7:00:00 AM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth

    Thomas Wiggans appointed Executive Chairperson  Jasper to host an investor webinar on January 8th at 8:00am ET to present updated data from the BEACON study in CSU and the open-label extension study in CSU and CIndU REDWOOD CITY, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper or the Company), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, announced that its Board of Directors has appointed Jeet Mahal as President and Chief Executive Officer

    1/7/26 4:30:00 PM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation

    Reductions in airway hyperresponsiveness and suppressed eosinophilic response at both 6 weeks and 12 weeks observed after a single 180mg dose of Briquilimab in the ETESIAN Study Preliminary data from ETESIAN study supports further development of briquilimab in asthma Jasper also announces completion of internal BEACON study investigation noting no deviations or issues with drug product utilized Jasper to host conference call and webinar today at 8:00 a.m. ET REDWOOD CITY, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117)

    12/2/25 7:00:00 AM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $JSPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rodman & Renshaw initiated coverage on Jasper Therapeutics with a new price target

    Rodman & Renshaw initiated coverage of Jasper Therapeutics with a rating of Buy and set a new price target of $17.00

    1/13/26 10:20:49 AM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Jasper Therapeutics downgraded by BMO Capital Markets with a new price target

    BMO Capital Markets downgraded Jasper Therapeutics from Outperform to Market Perform and set a new price target of $4.00

    7/8/25 8:30:26 AM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Jasper Therapeutics downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded Jasper Therapeutics from Outperform to Sector Perform and set a new price target of $5.00

    7/8/25 8:30:05 AM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $JSPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by CEO and President Mahal Jeetinder Singh

    4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

    2/10/26 4:00:23 PM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by President, CEO and Director Martell Ron

    4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

    1/5/26 7:30:55 PM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chief Operating Officer Mahal Jeetinder Singh

    4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

    1/5/26 7:30:34 PM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $JSPR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Wiggans Thomas G bought $99,630 worth of Voting Common Stock (41,000 units at $2.43) (SEC Form 4)

    4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

    9/24/25 4:01:57 PM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Lucas Svetlana bought $48,600 worth of Voting Common Stock (20,000 units at $2.43) (SEC Form 4)

    4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

    9/24/25 4:01:38 PM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Martell Ron bought $99,630 worth of Voting Common Stock (41,000 units at $2.43), increasing direct ownership by 124% to 74,118 units (SEC Form 4)

    4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

    9/24/25 4:01:19 PM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $JSPR
    Leadership Updates

    Live Leadership Updates

    View All

    Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors

    REDWOOD CITY, Calif., June 19, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced the appointment of Svetlana Lucas, Ph.D., to Jasper's Board of Directors (the Board), effective as of June 18, 2024. Separately, Anna French, D. Phil., stepped down from the Board, effective as of June 18, 2024. "We are pleased to welcome Svetlana, an experienced and accomplished biopharmaceutical executive, to our B

    6/19/24 8:00:00 AM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Jasper Therapeutics Announces Appointment of Thomas G. Wiggans as Chairperson of the Board of Directors

    REDWOOD CITY, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced the appointment of Thomas G. Wiggans, a veteran biopharmaceutical executive, as Chairperson of Jasper's Board of Directors (the Board), effective immediately. Bill Lis is stepping down as Chairperson and will re

    11/1/23 8:00:00 AM ET
    $DERM
    $JSPR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Jasper Therapeutics Strengthens Management Team with Key Appointments

    Patricia Carlos Appointed Senior Vice President of Regulatory Affairs and Quality Annette Marcantonio Appointed Vice President of Clinical Operations REDWOOD CITY, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria (CSU), lower to intermediate risk myelodysplastic syndromes (LR-MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of two seasoned pharma industry executives to its regulatory affairs, quality and clinical operations

    8/2/23 8:00:00 AM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $JSPR
    Financials

    Live finance-specific insights

    View All

    Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria

    67% of additional patients (n=6) enrolled in the BEACON study achieved a complete response at 12 weeks with a mean UAS7 reduction of 31 points  75% of CSU participants (n=36) enrolled in the open label extension study achieved a complete response or well controlled disease at 12 weeks With a median duration of follow up of more than 200 days on 63 participants in the open label extension study, KIT related AEs were low in frequency and predominantly low-grade events that resolved while on study BEACON and open label extension data sets are now sufficient to select doses for the Phase 2b study of briquilimab in CSU planned to commence in the second half of 2026 Company to host conference

    1/8/26 7:00:00 AM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation

    Reductions in airway hyperresponsiveness and suppressed eosinophilic response at both 6 weeks and 12 weeks observed after a single 180mg dose of Briquilimab in the ETESIAN Study Preliminary data from ETESIAN study supports further development of briquilimab in asthma Jasper also announces completion of internal BEACON study investigation noting no deviations or issues with drug product utilized Jasper to host conference call and webinar today at 8:00 a.m. ET REDWOOD CITY, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117)

    12/2/25 7:00:00 AM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

    11 of 12 participants (92%) enrolled in the 180mg cohort achieved a complete response 12 of 12 participants (100%) in the 180mg cohort achieved a clinical response Tryptase levels below the lower limit of quantification observed in 10 of 12 participants (83%) No serious adverse events and no grade 3 or higher adverse events reported in the 180mg cohort Company to host conference call and webinar on Monday, June 16, at 8:00 a.m. EDT REDWOOD CITY, Calif., June 14, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell drive

    6/14/25 10:00:23 AM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $JSPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Jasper Therapeutics Inc.

    SC 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)

    11/14/24 6:01:49 PM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Jasper Therapeutics Inc.

    SC 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)

    11/14/24 3:32:57 PM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Jasper Therapeutics Inc.

    SC 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)

    11/4/24 12:05:53 PM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care